Table 1 Characteristics of the hypertensive patients in the two treatment groups.
Irbesartan group2 | Atenolol group2 | |
|---|---|---|
Number of patients | 48 | 49 |
Age (years) | 54 ± 8 | 54 ± 8 |
Gender (proportion females) | 37% | 31% |
Height (m) | 1.74 ± 0.09 | 1.73 ± 0.09 |
Weight (kg) | 83 ± 15 | 82 ± 14 |
Smokers trial start (%) | 29 | 18 |
Baseline fs-cholesterol (mM) | 6.1 ± 1.0 | 5.8 ± 1.1 |
Baseline fb-glucose (mM) | 5.7 ± 3.1 | 5.2 ± 2.5 |
Pre-treatment SBP1 (mmHg) | 164 ± 18 | 160 ± 20 |
Pre-treatment DBP1 (mmHg) | 104 ± 7 | 103 ± 8 |
Change in SBP at 12 weeks (mmHg) | -16 ± 20 | -11 ± 16 |
Change in DBP at 12 weeks (mmHg) | -9.0 ± 11 | -12 ± 7.7 |